Reply to M. Horiguchi et al

J Clin Oncol. 2018 Mar 1;36(7):721. doi: 10.1200/JCO.2017.76.5339. Epub 2018 Jan 16.

Authors

Dirk Schadendorf¹, Joel Jiang¹, Thomas Kelleher¹, Michael A Postow¹

Affiliation

¹ Dirk Schadendorf, University Hospital Essen and the German Cancer Consortium, Essen, Germany; Joel Jiang and Thomas Kelleher, Bristol-Myers Squibb, Princeton, NJ; and Michael A. Postow, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.

PMID: 29337639
DOI: 10.1200/JCO.2017.76.5339

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Ipilimumab
Melanoma*
Nivolumab*

Substances

Ipilimumab
Nivolumab